Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The present study aimed to investigate whether red blood cell distribution width (RDW) was an independent prognosis factor for patients with glioma after surgery. Potential studies were found in four databases including PubMed, Embase, China National Knowledge Infrastructure and the Cochrane Library on 21st July, 2022. To evaluate the prognosis after surgery, hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to calculate the overall survival (OS) of patients with glioma. Stata V16.0 software was used for data analysis. A total of 8 studies were included, involving 1,468 patients. After collecting and analyzing the data, RDW was demonstrated to be a prognostic factor for OS of patients with glioma (HR=1.51; I=0.00%; 95% CI, 1.29-1.74; P<0.01). Patients with high preoperative RDW levels had a high risk of poor survival after neurosurgery. High preoperative RDW levels may be associated with poor prognosis and warrant further clinical attention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12365894 | PMC |
| http://dx.doi.org/10.3892/ol.2025.15217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.
Front Immunol
September 2025
Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Gliomas are the most common primary malignant tumors of the central nervous system (CNS), and despite progress in molecular diagnostics and targeted therapies, their prognosis remains poor. In recent years, immunotherapy has emerged as a promising treatment modality in cancer therapy. However, the inevitable immune evasion by tumor cells is a key barrier affecting therapeutic efficacy.
View Article and Find Full Text PDFAdvances in neuroscientific mechanisms and therapies for glioblastoma.
iScience
September 2025
Department of Molecular Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, QingDao, Shandong 266300, China.
Gliomas are common primary brain tumors in the central nervous system, characterized by invasiveness, heterogeneity, and drug resistance, posing a threat to patients' lives. Glioblastoma (IDH wild-type) exhibits the highest invasiveness and mortality rate, making it a challenging therapeutic target. This review first outlines the characteristics of gliomas and their impact on the nervous system, then explores the pathological mechanisms and unique behaviors of glioblastoma (IDH wild-type), as well as the influence of the nervous system on its occurrence and progression.
View Article and Find Full Text PDFPredictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study.
Front Oncol
August 2025
Department of Neurosurgery, Tengzhou Central People's Hospital, Tengzhou, Shandong, China.
Background: The objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.
Methods: A retrospective, single-center analysis was conducted on 103 patients with HGG who received BEV treatment. The enrolled patients were grouped based on their different biomarker statuses.
Prognostic value of [F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
Eur J Nucl Med Mol Imaging
September 2025
Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Purpose: Amino acid PET with [F]-fluoroethylthyrosine ([F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.
View Article and Find Full Text PDFPhotodynamic therapy for glioblastoma: a narrative review.
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDF